Brexpiprazole: A Review in Schizophrenia

CNS Drugs

Volumn 30, Issue 4, 2016, Pages 335-342

  Garnock Jones, Karly P ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; BREXPIPRAZOLE; CHOLESTEROL; CREATINE KINASE; CYTOCHROME P450; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; GLUCOSE; PROLACTIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 7 RECEPTOR; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; ARTICLE; BARNES AKATHISIA SCALE; BINDING AFFINITY; BODY TEMPERATURE DISORDER; BODY WEIGHT DISORDER; CHILD PUGH SCORE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; DYSTONIA; END STAGE RENAL DISEASE; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INHIBITORY CONCENTRATION; INSOMNIA; INTRINSIC ACTIVITY; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); NERVE FIBER GROWTH; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; PYRAMIDAL SIGN; RADIOACTIVITY; RECOMMENDED DRUG DOSE; RELAPSE; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SEVERE HEPATIC IMPAIRMENT; SIDE EFFECT; SIMPSON-ANGUS SCALE; STEADY STATE; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; TREMOR; VOLUME OF DISTRIBUTION; WEIGHT GAIN; ANIMAL; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; QUINOLONES; SCHIZOPHRENIA; THIOPHENES;

EID: 84962277962     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0325-8     Document Type: Article

References (28)

1. Zajdel P, Partyka A, Marciniec K, et al. Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents? Future Med Chem. 2014;6(1):57–75.
2. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management (cg178). 2014. http://www.nice.org.uk/. Accessed 2 Mar 2016.
3. Citrome L. Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today. 2015;51(7):397–414.
4. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.
5. ® (brexpiprazole tablets). 2015. http://www.accessdata.fda.gov. Accessed 2 Mar 2016.
6. McKeage K. Adjunctive brexpiprazole: a review in major depressive disorder. CNS Drugs. 2016. doi:10.1007/s40263-016-0320-0.
7. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
8. Oosterhof CA, El Mansari M, Blier P. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351(3):585–95.
9. Goff DC. Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry. 2015;172(9):820–1.
10. Ishima T, Futamura T, Ohgi Y, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015;25(4):505–11.
11. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–14.
12. Lerdrup L, Arnt J, Maeda K, et al. Brexpiprazole reduces impulsive behaviour of rats in a delayed discounting test and 5-choice-serial-reaction-time-test [abstract no. 733]. Biol Psychiatry. 2015;77(9 Suppl 1):273S–4S.
13. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124(Suppl C):245–9.
14. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25(3):356–64.
15. Otsuka Pharmaceutical Co Ltd. Study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 and aripiprazole for treatment of acute schizophrenia [NCT00905307]. 2015. http://www.clinicaltrials.gov. Accessed 2 Mar 2016.
16. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–80.
17. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.
18. Marder SR, Hakala MJ, Gislum M, et al. An interventional, multicenter, randomized, double-blind, placebo-controlled, active reference, flexible dose study of brexpiprazole in adults with acute schizophrenia [abstract]. In: 24th European Congress of Psychiatry; 2016.
19. H. Lundbeck A/S. Brexpiprazole in patients with acute schizophrenia [NCT01810380]. 2015. http://www.clinicaltrials.gov. Accessed 22 Feb 2016.
20. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study [abstract no. 560]. In: 70th Society of Biological Psychiatry Annual Meeting; 2015.
21. Weiss C, Zhang P, Hakala MJ, et al. Efficacy and safety of brexpiprazole in schizophrenia: meta-analysis of three double-blind, randomized, placebo-controlled phase 3 studies [abstract]. In: 24th European Congress of Psychiatry; 2016.
22. Skuban A, Correll CU, Kane JM, et al. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies [abstract no. 2089994]. In: 15th International Congress on Schizophrenia Research; 2015.
23. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978–97.
24. Hobart M, Ouyang J, Forbes A, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study [abstract no. 70]. In: American Society of Clinical Psychopharmacology annual meeting; 2015.
25. Correll CU, Skuban A, Ouyang J, et al. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies [abstract no. 2089877]. In: 15th International Congress on Schizophrenia Research; 2015.
26. Eramo A, Skuban A, Ouyang J, et al. Incidence, onset, duration and severity of akathisia with brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies [abstract no. 78]. In: The American Society of Clinical Psychopharmacology Annual Meeting; 2015.
27. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
28. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248–54.